Establishing a Case for Anti-complement Therapy in Membranous Nephropathy
| Autor: | Sergey V. Brodsky, John P. Shapiro, Xiaolan Lily Zhang, Salem Almaani, Michael L. Merchant, Anjali A. Satoskar, Cherri Bott, John Klein, Juan M. Mejia-Vilet, Daniel J. Birmingham, Brad H. Rovin, Samir V. Parikh, Lianbo Yu, Tibor Nadasdy, Sethu Madhavan, Huijuan Song, Isabelle Ayoub |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
complement protein
Pathology medicine.medical_specialty 030232 urology & nephrology 030204 cardiovascular system & hematology lcsh:RC870-923 03 medical and health sciences 0302 clinical medicine Complement Receptor Type 1 Membranous nephropathy Translational Research medicine Kidney biology business.industry membranous nephropathy proteomic analysis lcsh:Diseases of the genitourinary system. Urology medicine.disease Complement system medicine.anatomical_structure Nephrology Lectin pathway biology.protein Vitronectin business Complement membrane attack complex Kidney disease |
| Zdroj: | Kidney International Reports, Vol 6, Iss 2, Pp 484-492 (2021) Kidney International Reports |
| ISSN: | 2468-0249 |
| DOI: | 10.1016/j.ekir.2020.11.032 |
| Popis: | Introduction Membranous nephropathy (MN) is a common cause of adult nephrotic syndrome that progresses to end-stage kidney disease in up to 40% of cases. It is an autoimmune disease characterized by glomerular subepithelial deposits containing IgG. In experimental MN, these deposits activate complement and cause kidney damage. The role of complement in human MN is less clearly defined. To address this, the current study focused on the role of complement in 2 independent primary (p) MN cohorts. Methods Glomeruli were isolated by laser capture microdissection and analyzed by mass spectrometry, focusing on complement proteins, from kidney biopsy specimens from a pMN cohort (n = 11) and from normal controls (n = 5). Immunohistological staining of kidney biopsy specimens for complement proteins was also done. In a second pMN cohort (n = 13), urine levels of Ba, C5a, and C5b-9 (membrane attack complex [MAC]) were measured. Results Mass spectrometry identified 8 complement pathway components (C1q, C3, C4, C5, C6, C7, C8, and C9) and 5 complement regulators (complement receptor type 1 [CR1], factor H [FH], FH-related protein 2 [FHR2], vitronectin, and clusterin). All complement levels were significantly higher in the MN groups than in the control group, except the level of CR1, which was lower. All pMN biopsy specimens showed negative or trace staining for C1q, positive staining for C3 and C4, and positive staining for at least 1 component of the lectin pathway. Urine Ba, C5a, and MAC were present in pMN, and their levels correlated (rBa,C5a = 0.87, rBa,MAC = 0.89, and rC5a,MAC = 0.97, P = .001 for each correlation). Conclusion Elevated glomerular levels of C3, C4, and components of MAC (C5b-9) and absent or decreased levels of the complement regulator CR1, along with increased levels of complement activation products in the urine, support the involvement of complement in the pathogenesis of MN. These data raise the possibility that anti-complement therapies may be effective in some forms of MN. Graphical abstract |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|